Skip to content

Comparison of Sublobectomy Versus Lobectomy for Low-Risk Type of Invasive Lung Adenocarcinoma <= 2cm by Intraoperative Frozen Sections: a Prospective and Multi-Center RCT Study

Comparison of Sublobectomy Versus Lobectomy for Low-Risk Type of Invasive Lung Adenocarcinoma <= 2cm by Intraoperative Frozen Sections: a Prospective and Multi-Center RCT Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026791
Enrollment
Unknown
Registered
2019-10-22
Start date
2019-12-01
Completion date
Unknown
Last updated
2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early-stage lung cancer

Interventions

Sponsors

Shanghai Pulmonary Hospital, Tongji University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Patient aged 20–79 years; 2. tumor size = 0.25); 5. Intraoperative frozen section confirmed invasive lung adenocarcinoma and without micropapillary patterns; 6. Intraoperative frozen section analysis was used to assess the status of resection margins; 7. Lung function could withstand both lung segmentectomy and lobectomy(FEV1 >= 70%); 8. Performance status of 0,1 or 2; 9. Written informed consent.

Exclusion criteria

Exclusion criteria: 1. The nodule is close to the lung hilus and is unable to perform segmentectomy; 2. Intraoperative frozen section confirmed with micropapillary patterns; 3. Patients suspected of lymph node positive by preoperative CT scans; 4. Previous imaging examination revealed distant metastasis; 5. Patients with severe damage to heart, liver and kidney function (grade 3 ~ 4, ALT and/or AST over 3 times the normal upper limit, Cr over the normal upper limit); 6. Patients with other malignant tumors; 7. Pregnant and lactating women; 8. Non prior chemotherapy, radiation therapy or any other therapies were performed; 9. Participated in other tumors within three months of relevant clinical subjects.

Design outcomes

Primary

MeasureTime frame
recurrence-free survival rate;

Secondary

MeasureTime frame
overall survival rate;

Countries

China

Contacts

Public ContactDong Xie

Shanghai Pulmonary Hospital

kongduxd@163.com+86 13918918907

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026